Kendler Kenneth S, Ohlsson Henrik, Sundquist Kristina, Sundquist Jan
Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Box 980126, Richmond, VA, 23298-0126, USA.
Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA.
Soc Psychiatry Psychiatr Epidemiol. 2017 Jul;52(7):877-886. doi: 10.1007/s00127-017-1398-5. Epub 2017 May 26.
Nationwide data have been lacking on drug abuse (DA)-associated mortality. We do not know the degree to which this excess mortality results from the characteristics of drug-abusing individuals or from the effects of DA itself.
DA was assessed from medical, criminal, and prescribed drug registries. Relative pairs discordant for DA were obtained from the Multi-Generation and Twin Registers. Mortality was obtained from the Swedish Mortality registry.
We examined all individuals born in Sweden 1955-1980 (n = 2,696,253), 75,061 of whom developed DA. The mortality hazard ratio (mHR) (95% CIs) for DA was 11.36 (95% CIs, 11.07-11.66), substantially higher in non-medical (18.15, 17.51-18.82) than medical causes (8.05, 7.77-8.35) and stronger in women (12.13, 11.52-12.77) than in men (11.14, 10.82-11.47). Comorbid smoking and alcohol use disorder explained only a small proportion of the excess DA-associated mortality. Co-relative analyses demonstrated substantial familial confounding in the DA-mortality association with the strongest direct effects seen in middle and late-middle ages. The mHR was highest for opiate abusers (24.57, 23.46-25.73), followed by sedatives (14.19, 13.11-15.36), cocaine/stimulants (12.01, 11.36-12.69), and cannabis (10.93, 9.94-12.03).
The association between registry-ascertained DA and premature mortality is very strong and results from both non-medical and medical causes. This excess mortality arises both indirectly-from characteristics of drug-abusing persons-and directly from the effects of DA. Excess mortality of opiate abuse was substantially higher than that observed for all other drug classes. These results have implications for interventions seeking to reduce the large burden of DA-associated premature mortality.
目前尚缺乏全国范围内与药物滥用(DA)相关的死亡率数据。我们不清楚这种额外死亡率在多大程度上是由药物滥用个体的特征导致的,还是由药物滥用本身的影响导致的。
从医疗、刑事和处方药登记处评估药物滥用情况。从多代和双胞胎登记处获取药物滥用情况不一致的相对配对个体。死亡率数据来自瑞典死亡率登记处。
我们研究了1955年至1980年在瑞典出生的所有个体(n = 2,696,253),其中75,061人出现了药物滥用情况。药物滥用的死亡风险比(mHR)(95%置信区间)为11.36(95%置信区间,11.07 - 11.66),非医疗原因导致的死亡率(18.15,17.51 - 18.82)显著高于医疗原因导致的死亡率(8.05,7.77 - 8.35),且女性(12.13,11.52 - 12.77)的死亡率高于男性(11.14,10.82 - 11.47)。合并吸烟和酒精使用障碍仅解释了与药物滥用相关的额外死亡率中的一小部分。共相关分析表明,在药物滥用与死亡率的关联中存在显著的家族混杂因素,在中年和中晚年观察到最强的直接影响。阿片类药物滥用者的mHR最高(24.57,23.46 - 25.73),其次是镇静剂(14.19,13.11 - 15.36)、可卡因/兴奋剂(12.01,11.36 - 12.69)和大麻(10.93,9.94 - 12.03)。
登记确定的药物滥用与过早死亡之间的关联非常强烈,且由非医疗和医疗原因共同导致。这种额外死亡率既间接源于药物滥用者的特征,也直接源于药物滥用的影响。阿片类药物滥用导致的额外死亡率显著高于所有其他药物类别。这些结果对旨在减轻与药物滥用相关的过早死亡的巨大负担的干预措施具有启示意义。